MedTrace Logo

Phospholipid Hypothesis of Depression: From Molecular Biology, Neuroimaging to Behaviour

NCT02615405 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2015-11-26

No results posted yet for this study

Summary

With the dissatisfaction of monoamine-based pharmacotherapy and the high comorbidity of physical illness in depression, the serotonin hypothesis seems to fail in approaching the etiology of depression. Based upon the evidence from epidemiological data, case-control studies of PUFAs compositions, and antidepressant effects in clinical trials, phospholipid polyunsaturated fatty acids (PUFAs) is enlightening a promising path to discover the unsolved of depression.

Conditions

Interventions

DIETARY_SUPPLEMENT

EPA

A daily treatment of 5 identical capsules of EPA (3.5 g/d) for Studies 1 \& 2.

DIETARY_SUPPLEMENT

DHA

A daily treatment of 5 identical capsules of DHA (1.75 g/d) for Studies 1 \& 2.

DIETARY_SUPPLEMENT

Placebo

A daily treatment of 5 identical capsules of placebo (high oleic oil) in single or divided administration for Study 1.

Sponsors & Collaborators

  • National Science and Technology Council, Taiwan

    lead OTHER_GOV

Principal Investigators

  • Kuan-Pin Su, MD PhD · China Medical University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02615405 on ClinicalTrials.gov